SCM
CLYM

Superstring Capital Management’s Climb Bio CLYM Stock Holding History

Superstring Capital Management’s Portfolio CLYM Stock Details CLYM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.79M Buy
521,082
+321,873
+162% +$3.32M 4.29% 11
2026
Q1 		$1.36M Buy
+199,209
New +$1.15M 0.97% 27
2025
Q1 		– Sell
-98,160
Closed -$177K – 52
2024
Q4 		$177K Buy
98,160
+64,336
+190% +$233K 0.15% 38
2024
Q3 		$172K Buy
+33,824
New +$239K 0.15% 28

Other funds holding CLYM

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Superstring Capital Management's CLYM Position: Q2 2026 in Review

Superstring Capital Management increased its Climb Bio (CLYM) stake by 162% in Q2 2026, buying an estimated $3.32M and bringing the position to 521,082 shares worth $6.79M. The position accounts for 4.29% of the portfolio, ranked #11.

Superstring Capital Management first reported a position in CLYM in Q3 2024 and has held it in 4 quarters since. 109 funds tracked by Wall St. Rank hold CLYM as of Q2 2026.

  • Superstring Capital Management held 521,082 shares of Climb Bio worth $6.79M as of Q2 2026.
  • Superstring Capital Management bought 321,873 Climb Bio shares in Q2 2026, an estimated $3.32M.
  • Climb Bio made up 4.29% of Superstring Capital Management's portfolio in Q2 2026, its #11 holding.
  • Superstring Capital Management first reported a position in Climb Bio in Q3 2024 and has held it in 4 quarters since.
  • 109 funds tracked by Wall St. Rank held Climb Bio as of Q2 2026.

Based on Superstring Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.